Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
咪啶酮 ONC201 治疗 AML IND125,203 的 Ph1/2 研究 (12/23/2014)
基本信息
- 批准号:9806956
- 负责人:
- 金额:$ 25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Project Summary/Abstract
Survival rates (app. 30 %) of acute myeloid leukemia (AML) have not been improved over 4 decades, except in
some specialized instances. The long term aim of this study is to increase the cure rates of AML through
clinical implementation of targeting a new cellular survival mechanism, i.e. mitochondrial (mt) unfolded protein
response (mtUPR). We are proposing to conduct a clinical Phase 1/2 trial of ONC201, a first-in-class
imipridone and to confirm and further investigate the underlying novel mechanism of action (MOA). We
discovered in extensive preclinical studies that ONC201 induces apoptosis in AML but not in normal cells.
Importantly, ONC201 has great efficacy in p53-mutated AML, the most chemotherapy-resistant subset, as well
as in p53 wild-type AML. Our preclinical studies further demonstrate that ONC201 eliminates functionally-
defined leukemia stem cells in patient-derived xenografts. Early trials initiated at MD Anderson show excellent
tolerability of ONC201, micromolar plasma concentrations, and early clinical responses. We previously
reported that ONC201 induces apoptosis mediated by the transcription factor ATF4, a hallmark of integrated
stress response (ISR). However, ONC201 did not induce all characteristic molecular changes associated with
classical ISRs (e.g., ER stress), suggesting an atypical MOA to induce ATF4. As break through progress
reported in this re-submission, we have discovered that ONC201 directly binds and activates the mitochondrial
protease, ClpP, resulting in selective mitochondrial proteolysis. The resultant reduction of mt protein pools
induces so-called mt protein folding stress (mtPFS) and the protective transcriptional response against mtPFS
termed mt unfolded protein response (mtUPR). Importantly, ATF4 is known to be induced through mtUPR,
connecting our previous findings on ATF4 in a way different from classical ISRs. We here hypothesize that
AML progenitor and stem cells are more susceptible to mtPFS than normal cells, and that ONC201 is targeting
a novel point of vulnerability in AML pathobiology. The proposed clinical trial in leukemia provides a unique
opportunity to thoroughly investigate this hypothesis. We will conduct a Phase 1/2 study of ONC201 in AML
(Aim 1), and evaluate the underlying MOA (Aim 2). The Phase 1 trial will determine the safety and preliminary
efficacy of ONC201 and Phase 2 the overall response rate. Changes in ATF4, mtUPR effector proteins, mt
function and biogenesis in AML cells will be investigated using standard immunoblot and PCR methods as well
as novel tools including CyTOF (single cell proteomics). We will also determine if ClpP, ATF4 and mtUPR
effector proteins are potential biomarkers of clinical response to ONC201. Changes in clonal architecture will
be monitored by flow cytometry and single-cell DNA sequencing. Genome-wide RNAseq will also be performed
to further elucidate MOA and potential resistance. We expect these studies, which are at the cutting edge of
our evolving knowledge of mitochondrial pathophysiology, to be developed into a highly effective and novel
concept for the treatment of AML.
项目总结/摘要
急性髓性白血病(AML)的生存率(约30%)在过去40年中没有改善,
一些特殊的例子。本研究的长期目标是通过以下方法提高AML的治愈率:
靶向新的细胞存活机制即线粒体(MT)未折叠蛋白的临床实施
响应(mtUPR)。我们建议进行ONC 201的临床1/2期试验,
并确认和进一步研究潜在的新的作用机制(MOA)。我们
在广泛的临床前研究中发现,ONC 201在AML中诱导凋亡,但在正常细胞中不诱导凋亡。
重要的是,ONC 201在p53突变的AML中也有很好的疗效,AML是最耐化疗的亚群,
如p53野生型AML。我们的临床前研究进一步证明,ONC 201在功能上消除了
在患者来源的异种移植物中定义白血病干细胞。在MD安德森开展的早期试验显示,
ONC 201的耐受性、微摩尔血浆浓度和早期临床反应。我们之前
报道ONC 201诱导由转录因子ATF 4介导的凋亡,ATF 4是整合的细胞凋亡的标志。
应激反应(ISR)。然而,ONC 201并没有诱导与细胞凋亡相关的所有特征性分子变化。
经典的ISR(例如,ER应激),表明非典型MOA诱导ATF 4。作为突破性进展
在这次重新提交的报告中,我们发现ONC 201直接结合并激活线粒体
蛋白酶,ClpP,导致选择性线粒体蛋白水解。由此产生的mt蛋白池的减少
诱导所谓的mt蛋白折叠应激(mtPFS)和针对mtPFS的保护性转录应答
称为mt未折叠蛋白反应(mtUPR)。重要的是,已知ATF 4通过mtUPR诱导,
以不同于经典ISR的方式将我们先前对ATF 4的发现联系起来。我们在此假设
AML祖细胞和干细胞比正常细胞对mtPFS更敏感,ONC 201靶向
AML病理生物学中的一个新的脆弱点。拟议中的白血病临床试验提供了一个独特的
有机会彻底调查这个假设。我们将在AML中进行ONC 201的I/II期研究
(Aim 1),并评估潜在的MOA(目标2)。1期试验将确定安全性和初步
ONC 201的疗效和2期的总体缓解率。ATF 4、mtUPR效应蛋白、mt
还将使用标准免疫印迹和PCR方法研究AML细胞中的功能和生物发生
作为新的工具,包括CyTOF(单细胞蛋白质组学)。我们还将确定ClpP、ATF 4和mtUPR是否
效应蛋白是对ONC 201的临床应答的潜在生物标志物。克隆结构的变化将
通过流式细胞术和单细胞DNA测序进行监测。还将进行全基因组RNAseq
以进一步阐明MOA和潜在抗性。我们希望这些研究,这是在尖端的,
我们不断发展的线粒体病理生理学知识,将发展成为一个高效和新颖的
治疗AML的概念。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL ANDREEFF其他文献
MICHAEL ANDREEFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL ANDREEFF', 18)}}的其他基金
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML
治疗靶向 p53 重新激活诱导的 OXPHOS 依赖性和应激反应,以克服 AML 中对 Venetoclax/HMA 的耐药性
- 批准号:
10356325 - 财政年份:2022
- 资助金额:
$ 25万 - 项目类别:
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML
治疗靶向 p53 重新激活诱导的 OXPHOS 依赖性和应激反应,以克服 AML 中对 Venetoclax/HMA 的耐药性
- 批准号:
10550265 - 财政年份:2022
- 资助金额:
$ 25万 - 项目类别:
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
咪啶酮 ONC201 治疗 AML IND125,203 的 Ph1/2 研究 (12/23/2014)
- 批准号:
10663157 - 财政年份:2019
- 资助金额:
$ 25万 - 项目类别:
P53 Activation as Novel Therapeutic Strategy for Acute Myelogenous Leukemia
P53 激活作为急性髓性白血病的新治疗策略
- 批准号:
8499746 - 财政年份:2013
- 资助金额:
$ 25万 - 项目类别:
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
联合抑制急性髓系白血病中的 CXCR4 和 FLT3-ITD 信号传导
- 批准号:
7897533 - 财政年份:2010
- 资助金额:
$ 25万 - 项目类别:
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
联合抑制急性髓系白血病中的 CXCR4 和 FLT3-ITD 信号传导
- 批准号:
8056055 - 财政年份:2010
- 资助金额:
$ 25万 - 项目类别:
Targeting Microenvironment / Leukemia Cell Interactions in CML
CML 中的靶向微环境/白血病细胞相互作用
- 批准号:
8000073 - 财政年份:2010
- 资助金额:
$ 25万 - 项目类别:
Non-genotoxic p53 activation as novel therapeutic concept for lymphoma
非基因毒性 p53 激活作为淋巴瘤的新治疗概念
- 批准号:
7715218 - 财政年份:2009
- 资助金额:
$ 25万 - 项目类别:
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta
Plerixafor/G-CSF 联合索拉非尼治疗带有 FLT3-ITD Muta 的急性髓性白血病
- 批准号:
7936811 - 财政年份:2009
- 资助金额:
$ 25万 - 项目类别:
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta
Plerixafor/G-CSF 联合索拉非尼治疗带有 FLT3-ITD Muta 的急性髓性白血病
- 批准号:
8324135 - 财政年份:2009
- 资助金额:
$ 25万 - 项目类别:
相似国自然基金
Incentive and governance schenism study of corporate green washing behavior in China: Based on an integiated view of econfiguration of environmental authority and decoupling logic
- 批准号:
- 批准年份:2024
- 资助金额:万元
- 项目类别:外国学者研究基金项目
A study on prototype flexible multifunctional graphene foam-based sensing grid (柔性多功能石墨烯泡沫传感网格原型研究)
- 批准号:
- 批准年份:2020
- 资助金额:20 万元
- 项目类别:
相似海外基金
RII Track-4: NSF: Fundamental study on hydrogen flow in porous media during repetitive drainage-imbibition processes and upscaling for underground energy storage
RII Track-4:NSF:重复排水-自吸过程中多孔介质中氢气流动的基础研究以及地下储能的升级
- 批准号:
2327317 - 财政年份:2024
- 资助金额:
$ 25万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 25万 - 项目类别:
Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
- 批准号:
2346565 - 财政年份:2024
- 资助金额:
$ 25万 - 项目类别:
Standard Grant
EAGER: Innovation in Society Study Group
EAGER:社会创新研究小组
- 批准号:
2348836 - 财政年份:2024
- 资助金额:
$ 25万 - 项目类别:
Standard Grant
RUI: Spectroscopic Characterization and Low Temperature Kinetic Study of Hydrogenated Aromatic Radicals
RUI:氢化芳香族自由基的光谱表征和低温动力学研究
- 批准号:
2348916 - 财政年份:2024
- 资助金额:
$ 25万 - 项目类别:
Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
- 批准号:
2346564 - 财政年份:2024
- 资助金额:
$ 25万 - 项目类别:
Standard Grant
Collaborative Research: EAGER: The next crisis for coral reefs is how to study vanishing coral species; AUVs equipped with AI may be the only tool for the job
合作研究:EAGER:珊瑚礁的下一个危机是如何研究正在消失的珊瑚物种;
- 批准号:
2333604 - 财政年份:2024
- 资助金额:
$ 25万 - 项目类别:
Standard Grant
JApan multicenter Mitral Annular Calcification mitral stenosis study: JAMAC study
日本多中心二尖瓣环钙化二尖瓣狭窄研究:JAMAC 研究
- 批准号:
24K11304 - 财政年份:2024
- 资助金额:
$ 25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Study on p-type doping of ultra wide bandgap rutile-structured germanium oxide
超宽带隙金红石结构氧化锗的p型掺杂研究
- 批准号:
24K17312 - 财政年份:2024
- 资助金额:
$ 25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
大規模一般住民コホートによる手の疼痛と中枢性感作に関する疫学調査 -ROAD study-
使用大规模普通人群队列进行手部疼痛和中枢敏化的流行病学调查 -ROAD 研究 -
- 批准号:
24K19590 - 财政年份:2024
- 资助金额:
$ 25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists